Anne Fortier

Contributor

Anne Fortier is VP of Drug Discovery and Development at Conscience and is a seasoned drug hunter with a PhD in Biochemistry from McGill University and a track record of delivering first-in-class small-molecule therapies, including inaxaplin, through senior roles at Vertex Pharmaceuticals.

1 Contribution
by Anne Fortier E. Richard Gold

Beating antibiotic resistance takes new policies, not just new drugs

As we mark World Antimicrobial Resistance (AMR) Awareness Week Nov. 18-24, the message is a familiar one: drug-resistant infections are rising, our antibiotics are losing their power, and we need new ones.

1 of 1